The synthesis from penicillin G of a series of potent pseudosymmetric inhibitors 11 a-k of HIV-1 proteinase is described. The 2-pyridyl substituted compounds 11a and 11j showed improved antiviral activity compared to their C2-symmetric counterparts 3 and 4.
References
1.
CoatesJ.A.V.IngallH.J.PearsonB.A.PennC.R.StorerR.WilliamsonC., and CameronJ. (1991) Carbovir: the (-) enantiomer is a potent and selective antiviral agent against human immunodeficiency virus in vitro. Antiviral Res15: 161–168.
2.
DebouckC. (1992) The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses8: 153–164.
3.
EricksonJ.NeidhartD.J.VanDrieJ.KempfD.J.WangX.C.NorbeckD.W.PlattnerJ.J.RittenhoseJ.W.TuronM.WideburgN.KohlbrennerW.E.SimmerR.HelfrichR.PaulD.A., and KniggeM. (1990) Design, activity and 2Å crystal structure of a C2-symmetric inhibitor complexed to HIV-1 protease. Science249: 527–533.
4.
GrayN.M.CameronJ.M.CammackN.CobleyK.N.HolmesD.S.HumberD.C.OrrD.C.PennC.R.PotterR.MadarS.H.WeingartenG.G., and BethellR.C. (1994) Discovery and analysis of a series of C2-symmetric HIV-1 proteinase inhibitors derived from penicillin. Anal Biochem216: 89–96.
5.
HolmesD.S.ClemensI.R.CobleyK.N.HumberD.C.KitchinJ.OrrD.C.PatelB.PaternosterI.L., and StorerR. (1993) Novel dimeric penicillin derived inhibitors of HIV-1 proteinase: interaction with the catalytic aspartates. Bioorg Med Chem Lett3: 503–508.
6.
HuffJ.R. (1991) HIV protease: a novel chemotherapeutic target for AIDS. J Med Chem34: 2305–2314.
7.
HumberD.C.CammackN.CoatesJ.A.V.CobleyK.N.OrrD.C.StorerR.WeingartenG.G., and WeirM.P. (1992) Penicillin derived C2-symmetric dimers as novel inhibitors of HIV-1 proteinase. J Med Chem35: 3080–3081.
8.
HumberD.C.BamfordM.J.BethellR.C.CammackN.CobleyK.N.EvansD.N.GrayN.M.HannM.M.OrrD.C.SaundersJ.ShenoyB.E.V.StorerR.WeingartenG.G., and WyattP.G. (1993) A series of penicillin derived C2-symmetric inhibitors of HIV-1 proteinase: synthesis, mode of interaction, and structure-activity relationships. J Med Chem36: 3120–3128.
9.
KayJ., and DunnB.M. (1990) Viral proteinases: weakness in strength. Biochim Biophys Acta1048: 1–18.
10.
KempfD.J.NorbeckD.W.CodacoviL.M.WangX.C.KohlbrennerW.E.WideburgN.E.PaulD.A.KniggeM.F.VasavanondaS.Craig-KennardA.SaldivarA.RosenbrookW.Jr.ClementJ.J.PlattnerJ.J., and EricksonJ. (1990) Structure-based C2-symmetric inhibitors of HIV protease. J Med Chem33: 2687–2689.
11.
KempfD.J.CodacoviL.M.WangX.C.KohlbrennerW.E.WideburgA.S.SaldivarA.VasavanondaS.MarshK.C.BryantP.ShamH.L.GreenB.E.BetebennerD.A.EricksonJ., and NorbeckD.W. (1993) Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol. J Med Chem36: 320–330.
12.
MartinJ.A. (1992) Recent advances in the design of HIV proteinase inhibitors. Antiviral Res17: 265–278.
13.
PauwelsR.BalzariniJ.BabaM.SnoeckR.ScholsD.HerdewijnP.DesmyterJ., and DeClercqE. (1988) Rapid and automated tetrazolium-based colorimetric assay for the determination of anti-HIV compounds. J Virol Methods20: 309–321.
14.
SchechterL., and BergerA. (1967) On the size of the active site in proteases: I. Papain. Biochem Biophys Res Commun27: 157–162.
